Farther Finance Advisors LLC Lowers Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Farther Finance Advisors LLC cut its position in The Cooper Companies, Inc. (NASDAQ:COO) by 9.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,097 shares of the medical device company’s stock after selling 334 shares during the quarter. Farther Finance Advisors LLC’s holdings in Cooper Companies were worth $285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in COO. Byrne Asset Management LLC bought a new position in shares of Cooper Companies in the 4th quarter worth $33,000. OFI Invest Asset Management bought a new position in shares of Cooper Companies in the 4th quarter worth $34,000. Brown Brothers Harriman & Co. increased its holdings in shares of Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock worth $46,000 after buying an additional 275 shares during the last quarter. West Financial Advisors LLC bought a new position in shares of Cooper Companies in the 4th quarter worth $49,000. Finally, UMB Bank n.a. grew its holdings in shares of Cooper Companies by 22.5% during the 4th quarter. UMB Bank n.a. now owns 773 shares of the medical device company’s stock valued at $71,000 after purchasing an additional 142 shares during the last quarter. Institutional investors own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on COO. Robert W. Baird reduced their target price on shares of Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. Citigroup reduced their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Stifel Nicolaus reduced their target price on shares of Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Piper Sandler reaffirmed an “overweight” rating and set a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a report on Friday, March 7th. Finally, Wells Fargo & Company increased their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a report on Friday, December 6th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $111.89.

Cooper Companies Trading Up 0.2 %

NASDAQ:COO opened at $80.04 on Wednesday. The company has a 50-day moving average price of $90.68 and a 200-day moving average price of $98.56. The Cooper Companies, Inc. has a 12 month low of $77.05 and a 12 month high of $112.38. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The stock has a market cap of $16.01 billion, a price-to-earnings ratio of 41.05, a P/E/G ratio of 2.25 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The firm had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. Equities analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.